Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

188 related articles for article (PubMed ID: 38693705)

  • 1. Clinical outcomes associated with neoadjuvant therapy for the treatment of resectable non-small cell lung cancer in real-world practice.
    Huang X; Pang G; Mao Z; Li B; Teng Z; Yang Y; Qiu Z; Chen X; Wang P
    Clin Respir J; 2024 May; 18(5):e13761. PubMed ID: 38693705
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy and safety of neoadjuvant immunotherapy plus chemotherapy followed by adjuvant immunotherapy in resectable non-small cell lung cancer: a meta-analysis of phase 3 clinical trials.
    Zhang W; Liang Z; Zhao Y; Li Y; Chen T; Li W; Chen Y; Wu P; Zhang H; Fang C; Li L
    Front Immunol; 2024; 15():1359302. PubMed ID: 38646542
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacodynamics of Pre-Operative PD1 checkpoint blockade and receptor activator of NFkB ligand (RANKL) inhibition in non-small cell lung cancer (NSCLC): study protocol for a multicentre, open-label, phase 1B/2, translational trial (POPCORN).
    Ahern E; Cubitt A; Ballard E; Teng MWL; Dougall WC; Smyth MJ; Godbolt D; Naidoo R; Goldrick A; Hughes BGM
    Trials; 2019 Dec; 20(1):753. PubMed ID: 31856909
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Is neoadjuvant immunotherapy necessary in patients with programmed death ligand 1 expression-negative resectable non-small cell lung cancer? A systematic review and meta-analysis.
    Zhang SL; Tian Y; Yu J; Zhang JH; Sun L; Huang LT; Ma JT; Han CB
    Lung Cancer; 2024 May; 191():107799. PubMed ID: 38669725
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy of neoadjuvant immunochemotherapy and survival surrogate analysis of neoadjuvant treatment in IB-IIIB lung squamous cell carcinoma.
    Liu J; Zhu L; Tang M; Huang X; Gu C; He C; Lv X; Hu J
    Sci Rep; 2024 Mar; 14(1):5523. PubMed ID: 38448498
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Perioperative Nivolumab in Resectable Lung Cancer.
    Cascone T; Awad MM; Spicer JD; He J; Lu S; Sepesi B; Tanaka F; Taube JM; Cornelissen R; Havel L; Karaseva N; Kuzdzal J; Petruzelka LB; Wu L; Pujol JL; Ito H; Ciuleanu TE; de Oliveira Muniz Koch L; Janssens A; Alexandru A; Bohnet S; Moiseyenko FV; Gao Y; Watanabe Y; Coronado Erdmann C; Sathyanarayana P; Meadows-Shropshire S; Blum SI; Provencio Pulla M;
    N Engl J Med; 2024 May; 390(19):1756-1769. PubMed ID: 38749033
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treatment patterns and clinical outcomes of patients with resectable non-small cell lung cancer receiving neoadjuvant immunochemotherapy: A large-scale, multicenter, real-world study (NeoR-World).
    Yang Z; Wang S; Yang H; Jiang Y; Zhu L; Zheng B; Fu H; Ma J; Xie H; Wang Z; He H; Xia C; Li R; Xu J; Han J; Huang X; Li Y; Zhao B; Ni C; Xing H; Chen Y; Wang J; Jiang Y; Song Y; Mao Y; Chen C; Yao F; Zhang G; Hu J; Xue Q; Gao S; He J;
    J Thorac Cardiovasc Surg; 2024 Feb; ():. PubMed ID: 38342430
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Neo-adjuvant chemo/immunotherapy in the treatment of stage III (N2) non-small cell lung cancer: a phase I/II pilot study.
    Ratto GB; Costa R; Maineri P; Alloisio A; Piras MT; D'Agostino A; Tripodi G; Rivabella L; Dozin B; Bruzzi P; Melioli G
    Int J Immunopathol Pharmacol; 2011; 24(4):1005-16. PubMed ID: 22230406
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The Value of Perioperative Immunotherapy for Non-Small Cell Lung Cancer: A Pool- and Meta-Analysis.
    Wu Y; Hu L; Zhang S; Zhang H
    Technol Cancer Res Treat; 2024; 23():15330338241258164. PubMed ID: 38872482
    [No Abstract]   [Full Text] [Related]  

  • 10. SAKK 16/14: Durvalumab in Addition to Neoadjuvant Chemotherapy in Patients With Stage IIIA(N2) Non-Small-Cell Lung Cancer-A Multicenter Single-Arm Phase II Trial.
    Rothschild SI; Zippelius A; Eboulet EI; Savic Prince S; Betticher D; Bettini A; Früh M; Joerger M; Lardinois D; Gelpke H; Mauti LA; Britschgi C; Weder W; Peters S; Mark M; Cathomas R; Ochsenbein AF; Janthur WD; Waibel C; Mach N; Froesch P; Buess M; Bohanes P; Godar G; Rusterholz C; Gonzalez M; Pless M;
    J Clin Oncol; 2021 Sep; 39(26):2872-2880. PubMed ID: 34251873
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Outcome of Patients With pN2 "Potentially Resectable" Nonsmall Cell Lung Cancer Who Underwent Surgery After Induction Chemotherapy.
    Spaggiari L; Casiraghi M; Guarize J; Brambilla D; Petrella F; Maisonneuve P; De Marinis F
    Semin Thorac Cardiovasc Surg; 2016 Summer; 28(2):593-602. PubMed ID: 28043483
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Interim analysis of the efficiency and safety of neoadjuvant PD-1 inhibitor (sintilimab) combined with chemotherapy (nab-paclitaxel and carboplatin) in potentially resectable stage IIIA/IIIB non-small cell lung cancer: a single-arm, phase 2 trial.
    Sun C; Liu Y; Zhang P; Wang X; Xu Y; Lin X; Ma X; Guo Y; Qiu S; Shao G; Yang Z; Ma K
    J Cancer Res Clin Oncol; 2023 Feb; 149(2):819-831. PubMed ID: 35192053
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Real-World Effectiveness and Prognostic Factors Analysis of Stages I-III Non-Small Cell Lung Cancer Following Neoadjuvant Chemo-Immunotherapy or Neoadjuvant Chemotherapy.
    Liu Z; Gao Z; Zhang M; Wang X; Gong J; Jiang S; Zhang Z
    Ann Thorac Cardiovasc Surg; 2022 Apr; 28(2):111-120. PubMed ID: 34776459
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Preliminary Efficacy Evaluation of Neoadjuvant Immunotherapy Combined with 
Chemotherapy in Resectable Non-small Cell Lung Cancer].
    Zhou S; Hao X; Yu D; Liu S; Cao X; Su C; Song X; Xiao N; Li Y; Yang W; Zhao D; Wang J; Liu Z; Xu S
    Zhongguo Fei Ai Za Zhi; 2021 Jun; 24(6):420-425. PubMed ID: 34024062
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Chemoradiotherapy versus surgery after neoadjuvant chemoimmunotherapy in patients with stage III NSCLC: a real-world multicenter retrospective study.
    Guan S; Sun J; Wang Y; Han S; Chen C; Yue D; Huang Y; Ren K; Wang J; Wang J; Zhao L
    Cancer Immunol Immunother; 2024 May; 73(7):120. PubMed ID: 38713243
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Neoadjuvant chemotherapy and radiotherapy followed by surgery in selected patients with stage IIIB non-small-cell lung cancer: a multicentre phase II trial.
    Stupp R; Mayer M; Kann R; Weder W; Zouhair A; Betticher DC; Roth AD; Stahel RA; Majno SB; Peters S; Jost L; Furrer M; Thierstein S; Schmid RA; Hsu-Schmitz SF; Mirimanoff RO; Ris HB; Pless M
    Lancet Oncol; 2009 Aug; 10(8):785-93. PubMed ID: 19604722
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A real-world comparison between neoadjuvant chemoimmunotherapy and chemotherapy alone for resectable non-small cell lung cancer.
    Zhang B; Xiao H; Pu X; Zhou C; Yang D; Li X; Wang W; Xiao Q
    Cancer Med; 2023 Jan; 12(1):274-286. PubMed ID: 35621048
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Two commonly used neoadjuvant chemoradiotherapy regimens for locally advanced stage III non-small cell lung carcinoma: long-term results and associations with pathologic response.
    Machtay M; Lee JH; Stevenson JP; Shrager JB; Algazy KM; Treat J; Kaiser LR
    J Thorac Cardiovasc Surg; 2004 Jan; 127(1):108-13. PubMed ID: 14752420
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Transitioning to Neoadjuvant Therapy for Resectable Non-Small Cell Lung Cancer: Trends and Surgical Outcomes in a Regionalized Pulmonary Oncology Network.
    Pilon Y; Rokah M; Seitlinger J; Sepesi B; Rayes RF; Cools-Lartigue J; Najmeh S; Sirois C; Mulder D; Ferri L; Abdulkarim B; Ezer N; Fraser R; Camilleri-Broët S; Fiset PO; Wong A; Sud S; Langleben A; Agulnik J; Pepe C; Shieh B; Hirsh V; Ofiara L; Owen S; Spicer JD
    Clin Lung Cancer; 2024 May; 25(3):e133-e144.e4. PubMed ID: 38378398
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Neoadjuvant chemotherapy and Avelumab in early stage resectable nonsmall cell lung cancer.
    Tfayli A; Al Assaad M; Fakhri G; Akel R; Atwi H; Ghanem H; El Karak F; Farhat F; Al Rabi K; Sfeir P; Youssef P; Mansour Z; Assi H; Haidar M; Abi Ghanem A; Khalifeh I; Boulos F; Mahfouz R; Youssef B; Zeidan Y; Bejjany R; Khuri F
    Cancer Med; 2020 Nov; 9(22):8406-8411. PubMed ID: 32991781
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.